Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Emergent Biosolutions, Inc.

White House Outlines New Monkeypox Vaccine Strategy: What You Need To Know

The White House unveiled the first phase of its national monkeypox vaccine strategy, with plans to send doses to areas with confirmed outbreaks. The U.S. Department of Health and Human Services plans to distribute 296,000 doses of the Bavarian Nordic A/S's (OTC:BVNRY) Jynneos vaccine, an already-developed monkeypox vaccine. The U.S. is releasing 56,000 doses of…

Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract

Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract

Emergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines.

SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M

Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc's (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. "It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders," said Robert Kramer, president…

Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco

According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc (NYSE:EBS) might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards. Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. "Despite major…

Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements

Emergent BioSolutions Inc (NYSE:EBS) reported Q1 sales of $307.5 million, down 10% Y/Y, beating the consensus of $283 million. Total product sales increased 72% to $237.1 million, while Contract development & manufacturing (CDMO) revenues declined 67% to $60.8 million. The decrease is primarily due to the company's decision to initiate maintenance and…

1

People

194,350 stories

Carolyn Maloney

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

AstraZeneca Plc

Bavarian Nordic

Emergent BioSolutions

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

382,632 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play